Disagree. He was very clear in his wording that the results would be out at the end of the quarter. If he was transparent than he would have said by years end. Again, inexcusable for someone in his position to not follow through. Minutes after the call I ask the board for their thoughts on his statement and everyone who replied agreed it would be in Q3.
Liz, there is no excuse for this blunder! Bottom line Riley is responsible for what he does and says. It's very disheartening to see that he once again is not following up on his words. It's inexcusable by all standards!
Bottom line Riley is responsible for what he does and says. It's very disheartening to see that he once again is not following up on his words. It's inexcusable by all standards!
-Binimetinib and encorafenib combination shows an emerging differentiated tolerability profile while maintaining expected levels of activity in BRAF-mutant melanoma-
-Binimetinib and CDK4/6 inhibitor combination shows promising activity in NRAS-mutant melanoma-
This is great news! T the 370 patients, we thank you and good luck.
The other ones to watch or do your DD on are OPK, ARIA, ACHN and ARRY.
U G L Y day, week, month and quarter for the bios! Picked up some SYN, OPK, IDRA and ARIA on the cheap today.
OK, that leaves us a little over a week for the results which means the PPS should rise leading up to the news.
"We continue to move SYN-004 through the clinical pathway and look forward to initiating our SYN-004 Phase 2b proof-of-concept trial expected later this quarter."
I'm assuming he means Q4 since there is only a few more days left in tis Q?
I think once their combos start to take off with news,so will the stock. They can still be bought out by JNJ
or anybody else willing to pay the right price
Once ALS 335 PC results are presented at AASLD in November ACHN PPS will start to gain traction. I expect a buyout by Q1 of next year. Say $23 per share.